Investigating a new RNA's role in aggressive thyroid cancer
Role of newly identified, thyroid-specific LincRNA in BRAFV600E thyroid carcinoma
['FUNDING_R01'] · BETH ISRAEL DEACONESS MEDICAL CENTER · NIH-10769868
This study is looking at a tough type of thyroid cancer called BRAFV600E-papillary thyroid carcinoma to see how a newly discovered RNA affects how the cancer uses iodine and survives, with the goal of finding better treatment options for patients like you.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BETH ISRAEL DEACONESS MEDICAL CENTER (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10769868 on ClinicalTrials.gov |
What this research studies
This research focuses on BRAFV600E-papillary thyroid carcinoma, a particularly aggressive form of thyroid cancer that is resistant to traditional treatments. The study aims to understand how a newly identified thyroid-specific long intergenic non-coding RNA (lincRNA) affects iodine metabolism and tumor cell survival. By exploring the cellular mechanisms involved, the researchers hope to identify new treatment strategies that could improve patient outcomes. The project utilizes advanced techniques such as CRISPR to manipulate gene expression and assess the impact on cancer cell behavior.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with BRAFV600E-papillary thyroid carcinoma who have shown resistance to current therapies.
Not a fit: Patients with other types of thyroid cancer or those who do not have the BRAFV600E mutation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with BRAFV600E thyroid carcinoma, potentially improving survival rates and reducing recurrence.
How similar studies have performed: Other research has shown promise in targeting similar epigenetic mechanisms in cancer treatment, suggesting that this approach could be viable.
Where this research is happening
BOSTON, UNITED STATES
- BETH ISRAEL DEACONESS MEDICAL CENTER — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: NUCERA, CARMELO — BETH ISRAEL DEACONESS MEDICAL CENTER
- Study coordinator: NUCERA, CARMELO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer